SEC Company Response from Ampio Pharmaceuticals, Inc. (AMPE) (CIK 0001411906) — May 1, 2020
Ampio Pharmaceuticals, Inc. (AMPE) (CIK 0001411906)
Date: May 1, 2020 · CIK: 0001411906 · Accession: 0001558370-20-004920
AI Filing Summary & Sentiment
File numbers found in text: 333-237723
Letter
Re: Ampio Pharmaceuticals, Inc.
ampe_Current_Folio_Corresp
May 1, 2020
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Acceleration Request for Registration Statement on Form S-3
File No. 333-237723
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Ampio Pharmaceuticals, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to May 4, 2020, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Squire Patton Boggs (US) LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request, please contact Leah Brownlee of Squire Patton Boggs (US) LLP at (216) 479-8549.
Sincerely,
AMPIO PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm ampe_Current_Folio_Corresp May 1, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Ampio Pharmaceuticals, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-237723 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Ampio Pharmaceuticals, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to May 4, 2020, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Squire Patton Boggs (US) LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. If you have any questions regarding this request, please contact Leah Brownlee of Squire Patton Boggs (US) LLP at (216) 479-8549. Sincerely, AMPIO PHARMACEUTICALS, INC. /s/ Daniel Stokely Name: Daniel Stokely Title: Chief Financial Officer cc: Leah Brownlee, Squire Patton Boggs (US) LLP 373 Inverness Parkway Suite 200 Englewood, CO 80112 USA www.ampiopharma.com